neurokinin-1 antagonist

(redirected from NK1 receptor antagonist)
Also found in: Wikipedia.

neurokinin-1 antagonist (NK1),

agent that blocks the action of substance Pm which is a peptide found in the brain and GI tract, which initiates its actions by binding to the neurokinin-1 receptor. Antagonists of the neurokinin-1 receptor have been shown to have antiemetic activity.
See also: substance P.
References in periodicals archive ?
Privately held Menlo Therapeutics is focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatological conditions, and for refractory chronic cough.
It combines palonosetron with netupitant, the new highly selective NK1 receptor antagonist, in a single capsule.
Aprepitant is an oral NK1 receptor antagonist approved as Emend more than a decade ago for prevention of chemotherapy-induced nausea and vomiting.
The filing of the NDA for CINVANTI is an important milestone, bringing us one step closer to a new NK1 receptor antagonist treatment option for cancer patients suffering from the debilitating side effects of chemotherapy, said Kimberly J.
Akynzeo targets two critical signaling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV.
Since its inception, Helsinn has built a comprehensive portfolio of market-leading products, such as Aloxi, the market-leading treatment for chemotherapy induced nausea and vomiting (CINV) and the next generation Akynzeo, the first approved fixed combination oral agent that targets two critical signaling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV.
The product is a proprietary intravenous formulation of aprepitant, a NK1 receptor antagonist intended for the prevention of CINV.
AKYNZEO is the first fixed combination oral agent that targets two distinct signaling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule.
Currently, the only injectable NK1 receptor antagonist approved in the US contains polysorbate 80, a surfactant, which may cause hypersensitivity reactions, infusion site reactions or other adverse reactions in some patients.
AKYNZEO is an oral fixed combination of a 5-HT3 receptor antagonist, palonosetron, and an NK1 receptor antagonist, netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
NEPA is a fixed-dose combination of a novel NK1 receptor antagonist (Netupitant) and the best-in-class 5-HT3 receptor antagonist palonosetron.